Search
for
Sort by
Research 451–480 of 1000+
- Verilich hair serum in reducing hair shedding: A Case Report series
- SUMMARIES OF PAPERS
- Hair Loss in Women
- Human hair follicle: reservoir function and selective targeting
- Nanotechnology in Dermatology
- Ovarian Hypertension: Polycystic Ovary Syndrome
- Oral Contraceptives and Cyproterone Acetate in Female Acne Treatment
- CLINICAL UPDATES IN HAIR
- Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing—A Molecular Meta-Analysis
- Menopausal Acne – Challenges And Solutions
- Dermatosis associated with menopause
- Toward Optimal Health: The Experts Discuss Facial Skin and Related Concerns in Women
- Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: an Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy (EAT) with Proxalutamide (The EAT-Proxa Biochemical AndroCoV-Trial)
- Hair Follicle Targeting with Nanoparticles
- Hirsutism: from Brazil to a place near you
- Acne
- Lipid nanocarriers as innovative strategies for hair regrowth
- Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
- A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
- The Effect of Drugs on Hair
- Female pattern hair loss
- INSULIN-LOWERING MEDICATIONS IN POLYCYSTIC OVARY SYNDROME
- Systemic causes of hair loss
- Hidradenitis Suppurativa/Acne Inversa/Dissecting Terminal Hair Folliculitis
- Artificial Intelligence in Hair Disorders: A Narrative Review
- Analysis of Female Pattern Hair loss
- Harmless Herbs? A Review of the Recent Literature
- Women’s Health Considerations for Lipid Management
- Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease
- Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy